MyFinsight
Home
Compare
About
Recent SEC Filings
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
Yarrow Bioscience, Inc. (YARW)
Yarrow Bioscience, Inc. (YARW)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Cash Flow Overview
Change in Cash
-$1,102K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sale and maturity ...
Stock-based compensation
Prepaid expenses and other asset...
Others
Negative Cash Flow Breakdown
General and administrative
Trade payables, accrued expenses...
Other segment items
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
Royalty revenues-Royalty
183
Research and development-Repibresib VYN201
192
Research and development-Research And Development Of VYN202
592
Other segment items
821
General and administrative
5,496
Total operating expenses
7,101
Operating loss
-6,918
Other income, net
434
Loss from continuing operations before income taxes
-6,484
Income tax expense
0
Loss from continuing operations
-6,484
Loss from discontinued operations, net of income taxes
-108
Net loss
-6,592
Depreciation
12
Stock-based compensation
910
Amortization of premium or discount on marketable securities
-21
Prepaid expenses and other assets and operating lease right-of-use assets
-462
Trade payables, accrued expenses, employee related obligations and other long-term liabilities
-844
Operating lease liabilities
0
Net cash used in operating activities
-6,073
Proceeds from sale and maturity of marketable securities
5,000
Purchases of marketable securities
0
Net cash provided by investing activities
5,000
Withholdings from exercise of options and issuance of shares for stock-based compensation arrangements, net
-29
Net cash used in financing activities
-29
(decrease) increase in cash and cash equivalents
-1,102
Cash and cash equivalents at beginning of the period
24,027
Cash and cash equivalents at end of the period
22,925
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
YARW Cash Flow Sankey Diagram
Sankey diagram visualizing YARW cash flow for the period
Proceeds from sale and
maturity of marketable...
$5,000K
Net cash provided by
investing activities
$5,000K
(decrease) increase in cash
and cash...
-$1,102K
Canceled cashflow
$5,000K
Stock-based compensation
$910K
Prepaid expenses and
other assets and...
-$462K
Depreciation
$12K
Net cash used in
operating activities
-$6,073K
Canceled cashflow
$1,384K
Net cash used in
financing activities
-$29K
Net loss
-$6,592K
Trade payables,
accrued expenses,...
-$844K
Amortization of premium or
discount on marketable...
-$21K
Withholdings from exercise of
options and issuance of...
-$29K
Loss from continuing
operations
-$6,484K
Loss from
discontinued operations, net...
-$108K
Other income, net
$434K
Loss from continuing
operations before income...
-$6,484K
Canceled cashflow
$434K
Royalty
revenues-Royalty
$183K
Operating loss
-$6,918K
Canceled cashflow
$183K
Total operating
expenses
$7,101K
General and
administrative
$5,496K
Other segment items
$821K
Research and
development-Research And Development...
$592K
Research and
development-Repibresib VYN201
$192K
Buy us a coffee